Imatinib 400 Tablet 10’ct
Imatinib 400 mg is a prescription medication used to treat certain types of cancer, including:
- Chronic myeloid leukemia (CML) in adults and children
- Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in adults and children
- Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR gene re-arrangements in adults
- Advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement in adults
- Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) in adults
- Adjuvant treatment of adults with Kit (CD117)-positive GIST at significant risk of relapse following resection
- Unresectable dermatofibrosarcoma protuberans (DFSP) in adults
Description
Imatinib 400 mg is a prescription medication used to treat certain types of cancer, including:
- Chronic myeloid leukemia (CML) in adults and children
- Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in adults and children
- Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR gene re-arrangements in adults
- Advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement in adults
- Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) in adults
- Adjuvant treatment of adults with Kit (CD117)-positive GIST at significant risk of relapse following resection
- Unresectable dermatofibrosarcoma protuberans (DFSP) in adults
Packaging
- This is a 10-count bottle/package of the 400 mg strength of imatinib tablets.
- The tablets are typically packaged in high-density polyethylene (HDPE) bottles with child-resistant closures.
Appearance
- The imatinib 400 mg tablets are film-coated, oval-shaped, and light yellow to brownish orange in color.
- They are debossed with “NVR” on one side and “400” on the other side.
Composition
- Each film-coated tablet contains 400 mg of imatinib (as the mesylate salt).
- The inactive ingredients include microcrystalline cellulose, crospovidone, hydroxypropylcellulose, and magnesium stearate.
Manufacturer
- This specific 10-count package of imatinib 400 mg tablets is manufactured by Novartis Pharmaceuticals.
Key Benefits
- Treats certain types of blood cancers like chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL)
- Treats myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR gene rearrangements
- Treats advanced hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL)
- Treats unresectable and/or metastatic gastrointestinal stromal tumors (GIST)
- Can be used as adjuvant treatment for GIST after surgical resection
- Works by slowing or stopping the growth of cancer cells
Key Ingredients
- Each film-coated tablet contains 400 mg of imatinib (as the mesylate salt)
- The inactive ingredients include microcrystalline cellulose, crospovidone, hydroxypropylcellulose, and magnesium stearate
The key benefits of Imatinib 400 mg tablets are that they can treat various types of blood cancers and solid tumors by inhibiting the growth of cancer cells. The key ingredient is 400 mg of the active pharmaceutical ingredient imatinib mesylate.
ImatinibOral targeted therapy medication for cancer treatmentMoreTrade namesGleevec, Glivec, othersOther namesSTI-571Drug classTyrosine kinase inhibitorImatinib inhibits the BCR-ABL tyrosine kinase, which is the constitutively active tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It works by binding to the ATP pocket in the active site of BCR-ABL, preventing downstream phosphorylation of target proteins and inhibiting proliferation of cancer cells.Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (c-Kit). In vitro, it inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells that express an activating c-Kit mutation.By inhibiting these key tyrosine kinases involved in cancer cell growth and survival, imatinib effectively slows or stops the progression of various cancers including CML, GIST, and others.
Dosage
- The recommended adult dose for chronic myeloid leukemia (CML) in chronic phase is 400 mg taken once daily.
- For CML in accelerated phase or blast crisis, the recommended dose is 600 mg taken once daily.
- Doses of 400 mg or 600 mg can be taken once daily, while a daily dose of 800 mg should be taken as 400 mg twice a day.
- For patients unable to swallow the tablets, they can be dispersed in water or apple juice.
- Dose adjustments may be needed based on response, adverse reactions, or concomitant medications.
Storage
- Store Imatinib 400 mg tablets at room temperature between 15-30°C (59-86°F).
- Protect the tablets from moisture and direct light exposure.
- Do not store in the bathroom.
- Keep all medications away from children and pets.
Reviews
Based on clinical studies and real-world use:
- Imatinib has been shown to be effective in treating various types of cancer, including CML, GIST, and others.
- Many patients report good tolerability and response to treatment with Imatinib.
- Common side effects include nausea, vomiting, diarrhea, muscle cramps, and fatigue, but these are often manageable.
- Some patients may require dose adjustments or experience more serious adverse events like liver toxicity or fluid retention.
- Overall, Imatinib is considered an important and effective targeted therapy for the approved cancer indications when used appropriately. Order site Vitamins collection.com Contact 0307-7532291/0320-6421093
Reviews
There are no reviews yet.